1. Home
  2. CGBD vs IOVA Comparison

CGBD vs IOVA Comparison

Compare CGBD & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$12.67

Market Cap

906.2M

Sector

Finance

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.57

Market Cap

968.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGBD
IOVA
Founded
2012
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.2M
968.6M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CGBD
IOVA
Price
$12.67
$2.57
Analyst Decision
Hold
Buy
Analyst Count
7
12
Target Price
$13.70
$10.45
AVG Volume (30 Days)
518.4K
10.2M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
12.89%
N/A
EPS Growth
N/A
N/A
EPS
1.14
N/A
Revenue
$245,008,000.00
$250,425,000.00
Revenue This Year
$13.53
$60.94
Revenue Next Year
$4.24
$60.85
P/E Ratio
$11.25
N/A
Revenue Growth
2.55
175.62
52 Week Low
$11.55
$1.64
52 Week High
$18.64
$8.15

Technical Indicators

Market Signals
Indicator
CGBD
IOVA
Relative Strength Index (RSI) 49.19 61.08
Support Level $12.64 $2.08
Resistance Level $12.95 $2.60
Average True Range (ATR) 0.20 0.14
MACD -0.03 0.03
Stochastic Oscillator 14.86 92.29

Price Performance

Historical Comparison
CGBD
IOVA

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: